SCHEMBL16619602

SCHEMBL16619602

CC(O)c1cncc(CN(C)C(=O)O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.41
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
TDP1 Q9NUW8 2/20 0.35
KDM4E B2RXH2 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSP90AA1 P07900 1/20 0.35
PTGES O14684 1/20 0.34
RIPK1 Q13546 1/20 0.33
TACR1 P25103 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16629766 0.81 HTR2C (0.38) LMNACYP11B1CYP11B2RIPK1CHRNB2
SCHEMBL16619756 0.78 LMNA (0.40) LMNAHPGDCYP11B1CYP11B2NPC1
SCHEMBL16619456 0.76 POLB (0.44) LMNAHPGDNPC1RAB9ACA12
SCHEMBL16619604 0.75 LMNA (0.39) LMNAHPGDNPC1RAB9ACA12
SCHEMBL16619125 0.74 LMNA (0.38) LMNAHPGDNPC1RAB9ACA12
SCHEMBL16619332 0.73 NSD2 (0.42) LMNAHPGDNPC1RAB9ACA12
SCHEMBL16619128 0.69 CYP11B2 (0.38) CYP11B1CYP11B2KDM4E
SCHEMBL30513692 0.69 HPGD (0.43) LMNAHPGDNPC1RAB9ACA12
SCHEMBL29191706 0.68 MEN1 (0.59) LMNAHPGDNPC1RAB9ACA12
SCHEMBL10141639 0.68 CHRNB2 (0.44) LMNACHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052099-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2019-08-21 EP disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
EP-3052099-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS Merck Sharp & Dohme Corp. (US) 2016-08-10 EP disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 LMNA 1887/4885HPGD 944/4885CYP11B1 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.